WO2004087120A3 - Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension - Google Patents

Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension Download PDF

Info

Publication number
WO2004087120A3
WO2004087120A3 PCT/GB2004/001286 GB2004001286W WO2004087120A3 WO 2004087120 A3 WO2004087120 A3 WO 2004087120A3 GB 2004001286 W GB2004001286 W GB 2004001286W WO 2004087120 A3 WO2004087120 A3 WO 2004087120A3
Authority
WO
WIPO (PCT)
Prior art keywords
src kinase
hypertension
treatment
inhibitory activity
kinase inhibitory
Prior art date
Application number
PCT/GB2004/001286
Other languages
French (fr)
Other versions
WO2004087120A2 (en
Inventor
Jon Owen Curwen
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Jon Owen Curwen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Jon Owen Curwen filed Critical Astrazeneca Ab
Publication of WO2004087120A2 publication Critical patent/WO2004087120A2/en
Publication of WO2004087120A3 publication Critical patent/WO2004087120A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the use of a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke.
PCT/GB2004/001286 2003-03-29 2004-03-23 Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension WO2004087120A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307333.5A GB0307333D0 (en) 2003-03-29 2003-03-29 Therapeutic agent
GB0307333.5 2003-03-29

Publications (2)

Publication Number Publication Date
WO2004087120A2 WO2004087120A2 (en) 2004-10-14
WO2004087120A3 true WO2004087120A3 (en) 2005-01-27

Family

ID=9955830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001286 WO2004087120A2 (en) 2003-03-29 2004-03-23 Use of quinazoline derivatives with src kinase inhibitory activity for the treatment of hypertension

Country Status (2)

Country Link
GB (1) GB0307333D0 (en)
WO (1) WO2004087120A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP1741432A1 (en) * 2005-07-07 2007-01-10 Universitätsklinikum Freiburg The tyrosin kinase inhibitor Imatinib for the treatment of hypertension

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594480A (en) * 1966-10-31 1971-07-20 Pfizer Nitrogen heterocycles for therapeutic administration
US3772295A (en) * 1970-02-16 1973-11-13 Innothera Lab Sa Quinazoline derivatives
GB1349136A (en) * 1969-12-05 1974-03-27 Sandoz Ltd Quinazoline derivatives
US4640920A (en) * 1984-06-14 1987-02-03 John Wyeth & Brother Limited 4-(cinnolinylamino or quinazolinylamino)benzenesulphonamides and intermediates therefor
EP0607439A1 (en) * 1991-09-30 1994-07-27 Eisai Co., Ltd. Nitrogenous heterocyclic compound
EP0669324A1 (en) * 1993-09-10 1995-08-30 Eisai Co., Ltd. Quinazoline compound
WO1997003069A1 (en) * 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them
WO2000012497A2 (en) * 1998-08-28 2000-03-09 Scios Inc. Quinazoline derivatives as medicaments
WO2001045641A2 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
WO2001074360A1 (en) * 2000-04-05 2001-10-11 Astrazeneca Ab Therapeutic combinations of antihypertensive and antiangiogenic agents
WO2001094341A1 (en) * 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2002016352A1 (en) * 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
WO2002076977A2 (en) * 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors
WO2002076976A2 (en) * 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594480A (en) * 1966-10-31 1971-07-20 Pfizer Nitrogen heterocycles for therapeutic administration
GB1349136A (en) * 1969-12-05 1974-03-27 Sandoz Ltd Quinazoline derivatives
US3772295A (en) * 1970-02-16 1973-11-13 Innothera Lab Sa Quinazoline derivatives
US4640920A (en) * 1984-06-14 1987-02-03 John Wyeth & Brother Limited 4-(cinnolinylamino or quinazolinylamino)benzenesulphonamides and intermediates therefor
EP0607439A1 (en) * 1991-09-30 1994-07-27 Eisai Co., Ltd. Nitrogenous heterocyclic compound
EP0669324A1 (en) * 1993-09-10 1995-08-30 Eisai Co., Ltd. Quinazoline compound
WO1997003069A1 (en) * 1995-07-13 1997-01-30 Glaxo Group Limited Heterocyclic compounds and pharmaceutical compositions containing them
WO2000012497A2 (en) * 1998-08-28 2000-03-09 Scios Inc. Quinazoline derivatives as medicaments
WO2001045641A2 (en) * 1999-11-30 2001-06-28 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2001045751A1 (en) * 1999-12-22 2001-06-28 The Scripps Research Institute Angiogenesis and vascular permeability modulators and inhibitors
WO2001074360A1 (en) * 2000-04-05 2001-10-11 Astrazeneca Ab Therapeutic combinations of antihypertensive and antiangiogenic agents
WO2001094341A1 (en) * 2000-06-06 2001-12-13 Astrazeneca Ab Quinazoline derivatives for the treatment of tumours
WO2002016352A1 (en) * 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
WO2002076977A2 (en) * 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors
WO2002076976A2 (en) * 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors

Also Published As

Publication number Publication date
WO2004087120A2 (en) 2004-10-14
GB0307333D0 (en) 2003-05-07

Similar Documents

Publication Publication Date Title
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2007115289A8 (en) Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
WO2004082602A3 (en) Carboxamide spirohydantoin cgrp receptor antagonists
WO2007056163A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2004089286A3 (en) Novel compounds and compositions as protein kinase inhibitors
WO2006106311A3 (en) Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2007095188A3 (en) Dihydrodiazepines useful as inhibitors of protein kinases
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
MX2009004791A (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors.
WO2007133622A3 (en) Selective inhibitors of rock protein kinase and uses thereof
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2006031806A3 (en) 2-thiopyrimidinones as therapeutic agents
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
MX2009004785A (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors.
WO2004050040A3 (en) Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
WO2008079521A3 (en) Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007139816A3 (en) Thiophene-carboxamides useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase